PFE · 8-K · 20260804PR000094
Guidance and Outlook
PFIZER INC · 2026-08-04 · Importance 56 · Surprise 68 · No source text
Pfizer raised its full-year 2026 revenue guidance midpoint by $500 million, to a range of $60.5 billion to $62.5 billion. The revision reflects approximately $1.5 billion of better-than-expected non-COVID product performance, partly offset by a $1.0 billion reduction in expected COVID-19 product revenue to approximately $4.0 billion. Pfizer reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00, including an approximately $0.10 unfavorable impact from the Innovent transaction and a $650 million acquired in-process R&D charge expected in the third quarter of 2026. Guidance also incorporates an anticipated $1.1 billion unfavorable revenue impact from generic and biosimilar competition during 2026.
Key facts
- Raises full-year 2026 Revenue guidance by $500 million at the midpoint to a range of $60.5 to $62.5 billion source
- Full-year 2026 Revenue guidance reflects better than expected performance of non-COVID products by approximately $1.5 billion source
- Declared that adjusted SI&A expense guidance remains $12.5 to $13.5 billion and Adjusted R&D expense guidance remains $10.5 to $11.5 billion for 2026 source
- Reaffirms full-year 2026 Adjusted diluted EPS guidance in a range of $2.80 to $3.00 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +2.8% | Raises full-year 2026 Revenue guidance by $500 million at the midpoint to a range of $60.5 to $62.5 billion |
| operating_income | negative | committed | — | Declared that adjusted SI&A expense guidance remains $12.5 to $13.5 billion and Adjusted R&D expense guidance remains $10.5 to $11.5… |
| operating_income | negative | committed | — | Declared that adjusted SI&A expense guidance remains $12.5 to $13.5 billion and Adjusted R&D expense guidance remains $10.5 to $11.5… |